On July 7, 2020 Crescendo Biologics Ltd (Crescendo), the drug developer of novel, targeted T cell enhancing therapeutics reported that it has signed a pre-clinical collaboration agreement with Orano Med, a nuclear biotech company developing innovative targeted therapies in oncology (Press release, Crescendo Biologics, JUL 7, 2020, View Source [SID1234561698]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Orano Med is developing a new generation of Targeted Alpha Therapies (TAT) using the unique properties of lead-212 (²¹²Pb), a rare radioisotope. With this innovative approach, Orano Med is generating novel therapeutics capable of specifically recognising and destroying cancer cells while limiting the impact on nearby healthy tissues, a cutting-edge treatment for cancers with high unmet need.

Crescendo and Orano Med are working to exemplify the benefit of using Humabody VH for precise targeting of Orano Med’s TAT.

Theodora Harold, CEO of Crescendo Biologics, commented:
"Orano Med is one of the leaders in the field of nuclear medicine. Collaborating on its Targeted Alpha Therapy is an exciting opportunity for Crescendo to demonstrate the advantages of Humabody VHs for exquisitely targeted delivery of a potent alpha-emitting payload. We welcome the opportunity to work with the team at Orano Med."